Vanguard Group
NYMX

Vanguard Group’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Vanguard Group’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-204,033
Closed -$453K – 4457
2021
Q1 		$453K Buy
204,033
+25,274
+14% +$66.6K ﹤0.01% 4148
2020
Q4 		$443K Buy
178,759
+25,984
+17% +$57.4K ﹤0.01% 3975
2020
Q3 		$375K Sell
152,775
-7,654
-5% -$22.3K ﹤0.01% 3858
2020
Q2 		$570K Buy
+160,429
New +$507K ﹤0.01% 3739
2019
Q2 		– Sell
-92,057
Closed -$181K – 4189
2019
Q1 		$181K Sell
92,057
-362
-0.4% -$768 ﹤0.01% 3942
2018
Q4 		$121K Sell
92,419
-497
-0.5% -$910 ﹤0.01% 3975
2018
Q3 		$228K Buy
92,916
+3,405
+4% +$10.1K ﹤0.01% 3986
2018
Q2 		$300K Buy
89,511
+9,753
+12% +$37.5K ﹤0.01% 3919
2018
Q1 		$337K Buy
79,758
+4,002
+5% +$13.9K ﹤0.01% 3869
2017
Q4 		$250K Buy
75,756
+6,305
+9% +$23K ﹤0.01% 3893
2017
Q3 		$265K Buy
69,451
+788
+1% +$2.99K ﹤0.01% 3862
2017
Q2 		$302K Buy
+68,663
New +$282K ﹤0.01% 3827

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TEE
Tibra Equities Europe London, United Kingdom $90.4M AUM 37.81% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
WB
Webster Bank Waterbury, Connecticut $1.15B AUM 23.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Vanguard Group's NYMX Position: Q2 2021 in Review

Vanguard Group sold out of Nymox Pharmaceutical Corp (NYMX) in Q2 2021, closing a stake of 204,033 shares — an estimated $453K sold.

Vanguard Group first reported a position in NYMX in Q2 2017 and held it in 12 quarters. The position peaked at $570K in Q2 2020. 51 funds tracked by Wall St. Rank hold NYMX as of Q2 2021.

  • Vanguard Group reported no remaining Nymox Pharmaceutical Corp position as of Q2 2021 after selling out during the quarter.
  • Vanguard Group sold 204,033 Nymox Pharmaceutical Corp shares in Q2 2021, an estimated $453K.
  • Vanguard Group first reported a position in Nymox Pharmaceutical Corp in Q2 2017 and held it in 12 quarters.
  • Vanguard Group's Nymox Pharmaceutical Corp position peaked at $570K in Q2 2020.
  • 51 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q2 2021.

Based on Vanguard Group's 13F filing for Q2 2021, filed 13 Aug 2021.